All In Biotech

Drug Trial Radar · NCT07593391

An Open-label Study of NNZ-2591 in Pediatric Participants With Phelan-McDermid Syndrome

A Phase 3 Open-label Extension Study to Investigate the Long-term Safety and Efficacy of Orally Administered NNZ-2591 in Pediatric Participants With Phelan-McDermid Syndrome

Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

180

Planned (sponsor's estimate)

Start

Jun 8, 2026

Primary completion

Oct 29, 2028

Study completion Nov 12, 2028

Sponsor

Lead sponsor
Neuren Pharmaceuticals LimitedIndustry
Sponsor type
Industry
First posted
May 18, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 3 years, up to 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Phase 3, open-label extension, multicenter study will evaluate long-term safety, tolerability and efficacy of NNZ-2591 in pediatric participants with Phelan- McDermid Syndrome.

Conditions

  • Phelan-McDermid Syndrome

Interventions

  • NNZ-2591Drug

    The study drug will be administered twice daily orally.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Long-term safety and tolerability of NNZ-2591 as assessed by the incidence of adverse events across participantsTime frame: Baseline through Safety Follow-Up (Month 12)
  2. Long-term safety and tolerability of NNZ-2591 as assessed by changes from Baseline assessments of ECG parameters events across participants.Time frame: Baseline through Month 12
  3. Long-term safety and tolerability of NNZ-2591 as assessed by changes from Baseline assessments of ECG parameters events across participants.Time frame: Baseline through Safety Follow-Up (Month 12)
  4. Long-term safety and tolerability of NNZ-2591 as assessed by changes from Baseline assessments of ECG parameters events across participants.Time frame: Baseline through Safety Follow-Up (Month 12)
  5. Long-term safety and tolerability of NNZ-2591 as assessed by changes from Baseline assessments of ECG parameters events across participants.Time frame: Baseline through Safety Follow-Up (Month 12)
  6. Long-term safety and tolerability of NNZ-2591 as assessed by changes from Baseline assessments of ECG parameters events across participants.Time frame: Baseline through Safety Follow-Up (Month 12)
  7. Long-term safety and tolerability of NNZ-2591 as assessed by changes from Baseline assessments of ECG parameters events across participants.Time frame: Baseline through Safety Follow-Up (Month 12)
  8. Long-term safety and tolerability of NNZ-2591 as assessed by changes from Baseline assessments of vital sign parameters events across participants.Time frame: Baseline through Month 12
  9. Long-term safety and tolerability of NNZ-2591 as assessed by changes from Baseline assessments of vital sign parameters events across participants.Time frame: Baseline through Month 12
  10. Long-term safety and tolerability of NNZ-2591 as assessed by changes from Baseline assessments of vital sign parameters events across participants.Time frame: Baseline through Month 12
  11. Long-term safety and tolerability of NNZ-2591 as assessed by changes from Baseline assessments of vital sign parameters events across participants.Time frame: Baseline through Month 12
  12. Long-term safety and tolerability of NNZ-2591 as assessed by changes from Baseline assessments of vital sign parameters events across participants.Time frame: Baseline through Month 12
  13. Long-term safety and tolerability of NNZ-2591 as incidence of abnormal, clinically significant clinical laboratory parameters events across participants.Time frame: Baseline through Month 12
  14. Long-term safety and tolerability of NNZ-2591 as incidence of abnormal, clinically significant physical examination findings across participants.Time frame: Baseline through Month 12

Locations

12 sites in 1 country. Site status is shown where the registry gives one.

  • Neuren PMS-302 Site #116

    Birmingham, Alabama · Recruiting

  • Neuren PMS-302 Site#122

    Glendale, California · Recruiting

  • Neuren PMS-302 Site#103

    San Diego, California · Recruiting

  • Neuren PMS-302 Site#111

    San Rafael, California · Recruiting

  • Neuren PMS-302 Site#102

    Chicago, Illinois · Recruiting

  • Neuren PMS-302 Site#109

    Chevy Chase, Maryland · Recruiting

  • Neuren PMS-302 Site#106

    Brookline, Massachusetts · Recruiting

  • Neuren PMS-302 Site#104

    Lexington, Massachusetts · Recruiting

  • Neuren PMS-302 Site#101

    New York, New York · Recruiting

  • Neuren PMS-302 Site#108

    Cincinnati, Ohio · Recruiting

  • Neuren PMS-302 Site#115

    Houston, Texas · Recruiting

  • Neuren PMS-302 Site#113

    Charlottesville, Virginia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.